Haselmeier licenses Axis-D pen-injector technology to Stevanato Group for diabetes care

Haselmeier and Stevanato Group announced an exclusive agreement to license the Axis-D pen-injector technology and IP for diabetes care. Stevanato Group will manufacture the device at its facilities.

“We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in Diabetes.”einpresswire.com

• 1 source
• einpresswire.comHaselmeier Signs an Exclusive Agreement with Stevanato Group to License Axis-D Pen-injector Technology and Intellectual Property for the Therapeutic Area of Diabetes CareOct 7, 2019

Summarized from public sources; check the original articles before acting on it.